NVLG: Novolog achieved double-digit revenue growth and resumed profitability in 2024

About this update from Novolog (pharm Up 1966) Ltd.

Novolog reported 23% revenue growth and a return to profitability in 2024, driven by strong logistics performance and cost controls, while maintaining a robust balance sheet and dividend policy. Key risks include macroeconomic and regulatory factors. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Novolog (pharm Up 1966) Ltd.